500 likes | 549 Views
Learn about HIV/AIDS through the eyes of Dr. Pracheth, focusing on epidemiology, clinical features, drugs, treatment, prevention, and control methods. Understand the problem statement, transmission modes, laboratory diagnosis, counseling, ART, prophylaxis, and prevention programs. Dive into the world of HIV/AIDS and be informed.
E N D
HIV/AIDS Dr. Pracheth R. Assistant Professor-Community Medicine
Outline • Problem statement • Epidemiology • Clinical features • Drugs • Treatment • Prevention and Control
Problem statement-World • Emerging disease: early 1980s • 34.2 million PLHVA • Resurgence of TB • 1996: ART • 2010: CD4<350 cells/cu.mm
India • Group I: Maharashtra, Karnataka, Tamil Nadu, Andhra: 5%-high risk, 1%-antenatal women • Group II: Gujarat, Goa: 5%-high risk, <1%-antenatal • Group III: Low prevalence
Epidemiology • Agent factors: • Agent: • LAV, two short strands: RNA • Destroy T4 helper cells: subset of human T-lymphocytes • Reservoir: case/carriers
Continued…. • Source of infection: blood , semen , CSF, saliva, tears, breast milk • Host factors: • Age • Gender • High risk groups
Immunology • Healthy: twice-helper cells> suppressor cells • Ratio is reversed in AIDS • Total lymphocyte count< 500 cells/cu.mm • Opportunistic infections
Mode of transmission • Sexual transmission: • Women: larger surface area exposed, semen more HIV • Anal intercourse: abrasions on mucous membrane • Teenagers: cervix less efficient • Menopause: thinning of mucosa. • STD: 8-10 times- inflammation: T cells concentrate-genital area: easy spread
Continued….. • Blood contact: • Contaminated blood transfusion-whole blood cells, platelets, factors VIII, IX • Infected blood: risk-95% • Dose of virus • Contaminated needle , syringes lower • Drug abusers: exposure repeated.
Continued…. • Mother-to-child transmission: • Through placenta: delivery, breast feeding • Rates: 20-25% • Risk : high-newly infected
Incubation period • Uncertain: few months-10 years • Can be silent : many years • 75% infected-AIDS: 10 years
WHO Case Definition (2 major, 1 minor) • Major signs: • Weight loss ≥ 10% body weight • Chronic diarrhoea > 1 month • Prolonged fever > 1 month
Continued…. • Minor signs: • Persistent cough > 1month • Generalized dermatitis • H/O herpes zoster • Oropharyngeal candidiasis • Generalized lymphadenopathy
Expanded case definition • Adult/adolescent (>12 years) • HIV antibody test positive, 1/more: • ≥ 10% body weight loss/diarrhoea/fever-1 month • Cryptocoocal meningitis • Pulmonary/extrapulmonary TB
Continued…. • Kaposi sarcoma • Neurological impairment: daily activities • Oesophagial candidiasis • Recurrent pneumonia • Invasive cervical cancer
Clinical manifestations • Initial: 70%: no symptoms-5 years • Window period: before antibodies formed • Asymptomatic carrier state: • No signs, generalized lymph nodes +
Continued…. • AIDS related complex: • Damage-immune system: with/without opportunistic infections • Clinical signs
AIDS • End stage HIV infection • Opportunistic infections occur • Death: uncontrolled effects
Laboratory diagnosis • Screening tests: • Sensitive: ELISA • Specific: Western Blot-confirmatory • Virus isolation: expensive, slow • CD4 count: trend, every three months, < 350 cells/cu.mm
Counseling • Counseling: meaning • Pre-test • Post-test • Follow-up counseling
ART • Nucleoside Reverse Transcriptase Inhibitors (NRTI): Zidovudine, Didanosine, Stavudine, Lamuvidine • Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI): Nevirapine, Delavirdine, Efavirenz • Protease inhibitors (PI): Indinavir, Saquinavir, Ritonavir
Regimens First line (2NRTIs +1 NNRTI) • Zidouvidne+Lamivudine+Nevirapine • Stavuidne+Lamivudine+Nevirapine • Stavudine+Lamivudine+Efavirenz Second line • Protease Inhibitor+2 NRTI
Post-exposure prophylaxis • Combat occupational exposure • Primary prevention fails • First aid care: • Skin: wash soap, water • No antiseptics • Eye: irrigate: saline • Mouth: spit fluid, rinse thoroughly
Post-exposure prophylaxis • Establish eligibility: • First: within 72 hours, ideally : 2 hours • Counseling • Prescribe • Two NRTI, add Protease Inhibitor • For 28 days • Follow up
Standard precautions • Prevent cross infection • Safeguard health personnel • Avoid infection: society: hospital wastes
Specific prophylaxis • If CD4 < 200 : Pnemocystiscarnii • Cotrimoxazole, aerosolized pentamidine • M. avium complex: Rifabutin: if CD4< 200 • M. tuberculosis: 300 mg INH daily -9 months • Prevention of Parent to Child Transmission
Continued…. • Lifelong ART irrespective of CD4 • 6 weeks of Nevirapine syrup newborn, 12 weeks if duration ART < 24 weeks in mother
National AIDS Control Programme • In 1986: First case detected • In 1992: AIDS Control Programme I • In 1999: II • In 2007: III • In 2012: IV
NACP • First case detected ? • Total 99% population free • Reduce impact, zero transmission • Blood Safety • Counseling and HIV Testing • STD Control • Condom Promotion
Nacp • School AIDS Education • Ante-retroviral drugs (ART) • Prevention of Parent to Child Transmission (PPTCT) • HIV Testing for TB Patients
PORTIONS INTERNALS (6TH TERM) • Respiratory Infections: • Small Pox and Chicken Pox • Measles and Rubella • Diphtheria and Whooping Cough • Acute Respiratory Infections • Tuberculosis and RNTCP • Vector-borne diseases: • Malaria, dengue, filariasis, Japanese Encephalitis, Leishmaniasis, Chikungunya • NVBDCP
PORTIONS INTERNALS (6TH TERM) • Sexually Transmitted Infections: • STDs • HIV/AIDS and National Programme • Non-Communicable Diseases: • Diabetes • Hypertension